Adial Pharmaceuticals (ADIL) AI Stock Analysis

• Market Cap: $2.70M
• Dividend Yield: N/A
• Average Volume (3M): 746.19K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.81
• Revenue Growth: N/A
• EPS Growth: 78.52%
• Country: US
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.81
• Shares Outstanding: 1,427,970
• 10 Day Avg. Volume: 779,793
• 30 Day Avg. Volume: 746,186
• PEG Ratio: 0.01
• Price to Book (P/B): 0.70
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.57
• Enterprise Value/Market Cap: -1.58
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 15.08K
• Enterprise Value/Ebitda: 0.55
• 1Y Price Target: $8.00
• Price Target Upside: 3536.36% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -6.43
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $2.00 ▲(809.09% Upside)
• Action: Reiterated Date: 03/06/26
• Date: Action: Reiterated 03/06/26

The score is driven primarily by very weak financial performance (no revenue, ongoing losses, and persistent cash burn) and poor technicals (price far below key moving averages with negative momentum). Corporate events provide some offset via partnering/compliance improvements, but negative earnings-based valuation (loss-making) limits support.

Positive Factors

Regulatory Support

Legislative support for new clinical trial endpoints can streamline regulatory approval for AD04, enhancing Adial's strategic positioning and potentially accelerating market entry.

Leadership Stability

The appointment of Tony Goodman as COO ensures leadership continuity, which is crucial for strategic execution and operational stability as the company advances its clinical programs.

Regulatory Milestone

The FDA's approval of AD04's in vitro strategy is a key regulatory milestone, advancing the drug to Phase 3 trials and bringing it closer to commercialization, which is vital for future revenue generation.

Negative Factors

Financial Challenges

The lack of revenue and ongoing net losses highlight financial instability, which can hinder long-term growth and necessitate continued reliance on external funding.

Negative Cash Flow

Negative cash flow from operations indicates challenges in self-sustaining financial health, increasing dependency on external financing and potentially limiting strategic flexibility.

Operational Inefficiencies

Operational inefficiencies, as evidenced by negative EBIT and EBITDA, suggest difficulties in managing costs and achieving profitability, which could impact long-term viability.

Adial Pharmaceuticals Business Overview & Revenue Model

Company Description

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

How the Company Makes Money

Adial Pharmaceuticals generates revenue primarily through the development and potential commercialization of its lead product candidate, AD04, which is targeted at treating alcohol use disorder. The company aims to make money by obtaining regulatory approval for AD04 and then marketing it to healthcare providers and patients. Additionally, Adial may engage in strategic partnerships, licensing agreements, or collaborations with other pharmaceutical companies to enhance its market reach and share in the profits derived from sales of its products. Revenue streams may also include upfront payments, milestone payments, and royalties from these partnerships, but as a clinical-stage company, its earnings are contingent on successful product development and commercialization efforts.

Adial Pharmaceuticals Financial Statement Overview

Summary

Operating fundamentals are very weak: no revenue, persistent sizable net losses, and recurring negative operating cash flow/free cash flow indicating ongoing cash burn and reliance on external funding. The main offset is low leverage/minimal debt, which reduces near-term balance-sheet risk but does not fix profitability or cash burn.

Income Statement

The company has generated no revenue across the provided annual periods, while operating losses remain large and persistent (EBIT roughly -$6.9M to -$19.3M; net income losses also consistently negative). There is some improvement versus the peak loss year (2021), but profitability is still structurally weak with no visible path to margin expansion given the absence of sales.

Balance Sheet

Leverage is low (total debt is minimal to zero in most years and debt-to-equity is near zero), which reduces financial risk. However, equity is relatively small and returns on equity are deeply negative each year, reflecting ongoing losses that can pressure the capital base over time despite the low debt profile.

Cash Flow

Cash burn is heavy and recurring, with operating cash flow consistently negative (about -$6.5M to -$11.9M annually) and free cash flow generally negative as well. While cash burn improved versus 2021–2022 levels, the trajectory is uneven (including a sharp decline in free cash flow growth in 2025), and negative operating cash flow indicates continued reliance on external funding.

Breakdown	Dec 2025	Dec 2024	Mar 2024	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-565.00	0.00	-564.00	0.00	0.00
EBITDA	-7.80M	-8.28M	-7.00M	-10.86M	-17.69M
Net Income	-7.98M	-13.20M	-7.00M	-12.73M	-19.42M
Balance Sheet
Total Assets	6.67M	5.04M	4.74M	5.73M	7.63M
Cash, Cash Equivalents and Short-Term Investments	5.88M	3.75M	2.83M	4.00M	6.06M
Total Debt	0.00	0.00	0.00	207.38K	256.96K
Total Liabilities	1.40M	975.86K	653.51K	2.46M	4.13M
Stockholders Equity	5.28M	4.07M	4.08M	3.28M	3.51M
Cash Flow
Free Cash Flow	-6.49M	-6.92M	0.00	-11.19M	-12.01M
Operating Cash Flow	-6.49M	-6.92M	-6.81M	-11.19M	-11.95M
Investing Cash Flow	150.00K	0.00	1.50M	0.00	-34.02K
Financing Cash Flow	8.47M	7.85M	4.13M	9.13M	13.64M

Adial Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.22
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADIL, the sentiment is Negative. The current price of 0.22 is below the 20-day moving average (MA) of 2.18, below the 50-day MA of 3.82, and below the 200-day MA of 7.85, indicating a bearish trend. The MACD of -0.54 indicates Negative momentum. The RSI at 26.58 is Positive, neither overbought nor oversold. The STOCH value of 49.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ADIL.

Adial Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MTNB	45 Neutral	$4.08M	-1.19	-157.24%	―	―	25.19%
CLDI	45 Neutral	$2.31M	-0.36	―	―	―	87.42%
ADIL	44 Neutral	$2.70M	-0.46	-155.01%	―	―	78.52%
GLMD	44 Neutral	$3.35M	-1.00	-46.34%	―	―	70.71%
KPRX	44 Neutral	$7.72M	111.22	-32.58%	―	-100.00%	-463.97%

Adial Pharmaceuticals Corporate Events

Adial Pharmaceuticals Secures European Partnership for AD04 Commercialization

On March 3, 2026, Adial Pharmaceuticals announced a collaboration framework with Italy’s Molteni Farmaceutici for a proposed exclusive partnership to commercialize its lead addiction drug candidate AD04 in Europe, giving Molteni a period of exclusivity to assess clinical, regulatory and commercial requirements. The framework envisions upfront and milestone payments plus tiered royalties that could total nearly $60 million over time if AD04 successfully completes development and launches in Europe, marking Adial’s first major commercial partnership and a key step in building a European pathway as it prepares pivotal Phase 3 trials and optimizes its genotype-driven clinical and manufacturing strategy.

On February 26, 2026, the company was unable to convene a Special Meeting of Stockholders due to lack of quorum, delaying shareholder approval needed for the potential issuance of up to 13,823,512 common shares upon exercise of previously issued warrants. Under an existing inducement agreement, Adial must now call additional shareholder meetings every 90 days until it secures the required approval or the new warrants are no longer outstanding, prolonging uncertainty around this element of its capital structure.

The most recent analyst rating on (ADIL) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Adial Pharmaceuticals stock, see the ADIL Stock Forecast page.

Adial Pharmaceuticals Regains Nasdaq Compliance, Advances AD04 Program

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specializing in genetically targeted therapies for addiction, is advancing its lead candidate AD04 for Alcohol Use Disorder into a new Phase 3 program. The company is building on encouraging ONWARD Phase 3 data and a proprietary genetic test, while exploring broader indications such as opioid use disorder, gambling, and obesity.

On February 23, 2026, Adial received notice from Nasdaq that it had regained compliance with the exchange’s $1.00 minimum bid price rule after its shares closed at or above that level for ten consecutive business days from February 6 to February 20, 2026. The resolution of this listing issue, announced publicly on February 24, 2026, removes a key overhang on the stock as management highlights advanced strategic partnering discussions to support AD04’s next development phase and potential commercialization.

The most recent analyst rating on (ADIL) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Adial Pharmaceuticals stock, see the ADIL Stock Forecast page.

Adial Pharmaceuticals Implements Reverse Stock Split to Regain Compliance

On August 1, 2025, shareholders of Adial Pharmaceuticals approved a reverse stock split of the company’s common stock, and the board later set the final ratio at 1-for-25, with the split becoming legally effective at 11:59 p.m. Eastern Time on February 5, 2026; trading on a split-adjusted basis on the Nasdaq Capital Market under the existing ticker “ADIL” commenced on February 6, 2026. The move reduced Adial’s outstanding common shares from about 27.8 million to approximately 1.1 million without changing the total number of authorized shares, preserved proportional ownership aside from the cash-out of fractional shares, and adjusted outstanding equity awards and warrants, as the company sought to lift its per-share trading price to regain compliance with Nasdaq’s minimum $1.00 bid requirement and potentially broaden its appeal among institutional and retail investors.

The most recent analyst rating on (ADIL) stock is a Hold with a $0.20 price target. To see the full list of analyst forecasts on Adial Pharmaceuticals stock, see the ADIL Stock Forecast page.

Adial Pharmaceuticals announces immediate resignation of board director

On January 5, 2025, Adial Pharmaceuticals announced that James W. Newman, Jr., a non-employee director and member of both the Audit Committee and the Compensation Committee, resigned from the company’s Board of Directors effective immediately. The company stated that Newman’s departure was not the result of any disagreement regarding Adial’s operations, policies, or practices, suggesting a routine governance change rather than a shift in strategic direction or indication of internal conflict for investors and other stakeholders.

The most recent analyst rating on (ADIL) stock is a Hold with a $0.22 price target. To see the full list of analyst forecasts on Adial Pharmaceuticals stock, see the ADIL Stock Forecast page.